LTRN: 2Q:21 Results

On July 29, 2021, Lantern Pharma, Inc. (NASDAQ:LTRN) announced second quarter 2021 financial and operational results, filed its form 10-Q with the SEC and hosted a conference call to review the quarter's accomplishments. Lantern generated no revenues in the second quarter and expended $2.48 million on operations during the three month period producing a net loss of ($2.32) million, or ($0.21) per share. Cash burn in the second quarter was ($1.7) million, up markedly from the ($490,000) consumed in the prior year period. Lantern reacquired global rights to its candidate LP-100 from Allarity Therapeutics, publicized in a press release on July 27, 2021. The candidate is in Phase II trials that enrolled 9 out of 27 targeted subjects.